Latest Breaking News On - Tyrosine kinase inhibitor na - Page 1 : comparemela.com

Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.

Yasir elaminLocal consolidative therapyTyrosine kinase inhibitor naRearranged metastaticNon small cell lung cancerLung cancerMetastatic nsclcMetastatic lung cancerBrightstar trialBrightstar studyTyrosine kinase inhibitorTyrosine kinase inhibitionStudy designTrial designPatient characteristicsEfficacy data